Clinical Trial Update: Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial conducted at Cairo University evaluating Biobran MGN-3 (arabinoxylan rice bran) in combination with Interferon-Alpha for chronic hepati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Biobran MGN-3 (arabinoxylan from rice bran)
• Interferon-alpha (interferon alpha)

Snippet

Sponsor: Cairo University | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED